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Exposuretohepatitis Cvirus(HCV)usuallyresults inpersistent infectionthatoftendevelopsintochronicliverdisease.Interferon-
alpha (IFN) treatment comprises the foundation of current approved therapy for chronic HCV infection but is limited in overall
eﬃcacy. IFN is a major eﬀector of innate antiviral immunity and is naturally produced in response to viral infection when
viral pathogen-associated molecular patterns (PAMPs) are recognized as nonself and are bound by cellular pathogen recognition
receptors (PRRs), including Toll-like receptors (TLRs) and the RIG-I-like receptors (RLRs). Within hepatocytes, RIG-I is a major
PRR of HCV infection wherein PAMP interactions serve to trigger intracellular signaling cascades in the infected hepatocyte to
drive IFN production and the expression of interferon-stimulated genes (ISGs). ISGs function to limit virus replication, modulate
the immune system, and to suppress virus spread. However, studies of HCV-host interactions have revealed several mechanisms
of innate immune regulation and evasion that feature virus control of PRR signaling and regulation of hepatic innate immune
programs that may provide a molecular basis for viral persistence.
1.Introduction
In response to virus infection, signaling pathways within
mammalian cells direct a variety of intracellular events
that generate an antiviral state directly within the infected
cell. This antiviral innate immune response represents our
very frontline of immune defense against virus infection.
If this response is successful, exposure to the virus will
turn into an abortive, self-limiting infection, and the virus
will be cleared. It is the hepatic innate immune response
that imposes initial antiviral defenses against HCV infec-
tion [1]. This response is triggered when the infected
cell recognizes a molecular signature or PAMP within the
invading virus through the actions of cellular PRRs [2,
3]. The PAMP/PRR interaction initiates signaling cascades
that induce the expression of antiviral eﬀector genes [4,
5]. Viral protein and/or nucleic acid products comprise
an array of PAMP signatures that can engage speciﬁc
PRRs, including TLRs or the RLRs, RIG-I, and MDA5 [6–
9].
Upon virus infection and PAMP recognition, RLRs
and TLRs operate through independent signaling cascades
separated in part through the localization of the distinct
PRRs.RLRsarecytosolicwhereasTLRsaretypicallylocalized
within endosomes or on the cell surface. Nevertheless, both
sets of PRR signaling cascades can lead to the activation of
PAMP-driven transcription factors, IFN gene expression
and protein secretion, and ISG expression that results in
the immediate induction of the intracellular innate immune
response both within the infected cell and within bystander
cells that respond locally or systemically to the secreted
IFN [10]. Interferon regulatory factor- (IRF-) 3 and nuclear
factor-kappa B (NF-κB) are the ﬁrst transcription factors
activated in response to HCV infection of hepatocytes
(Figure 1(a)). During HCV infection, their activation
proceeds through RIG-I signaling, with likely contributions
from TLRs, whose signaling pathways promote IRF-3 and
NF-κB nuclear translocation and transactivation functions.
Other IRF family members, including IRF-1, IRF-5, and
IRF-7,contributetoinnate immune responses and should be2 Gastroenterology Research and Practice
considered important for immunity against HCV infection
[11, 12].
2.Toll-LikeReceptorsMediate Endosomal
PAMPRecognitionofHCV
Toll was ﬁrst identiﬁed as a transmembrane receptor regu-
lating insect morphogenesis [13]. Toll mutation also results
in increased susceptibility to fungi in Drosophila [14].
Ten members of human Toll-like receptors (TLRs) were
later identiﬁed as sensing receptors of various pathogen-
associated molecular patterns (PAMPs). Human TLRs are
expressed in a tissue-speciﬁc manner, and many are
expressed in dendritic cells (DCs) and macrophages [15].
Although each TLR detects a distinct set of PAMPs, a
common extracellular leucine-rich repeat (LRR) motif is
responsible for PAMP sensing. When the LRR engages a
PAMP, the TLR transmits a signal through the cytoplasmic
domain of the receptor to drive a signaling cascade that
results in the production of various cytokines that serve to
deﬁne the innate immune response and initiate immune cell
recruitment.
This signaling drives macrophages and DCs to diﬀer-
entiate into full-blown antigen-presenting cells to initiate
antigen-speciﬁc adaptiveimmunity.Inhumans, atleastthree
major TLRs are important in virus infection and immunity:
TLR3 [16–18], TLR7 [19–24], and TLR9 [25, 26], which
are typically expressed within endosomes. Double-stranded
RNA (dsRNA) PAMPs are detected by TLR3 whereas
TLR7 recognizes a speciﬁc uridine-rich ribonucleotide motif
within a single-strand RNA [27], and TLR9 recognizes DNA
PAMP motifs encoding CpG nucleotides [28, 29]. It has
also been reported that TLR2 and TLR4 are also involved
in inﬂammation responses during HCV infection [30–32].
Thus, TLR3 and TLR7 speciﬁcally recognize PAMPs that
accumulate during RNA virus infection, and each has been
shown to be important for innate immunity against HCV
infection either directly in hepatocytes (TLR3) or indirectly
through PAMP signaling of antigen-presenting cells (TLR3
and TLR7) that accumulate HCV products through their
phagocytic activity [15, 33, 34].
3.RLRsMediateCytosolic
RNAPAMP Recognition
Retinoic acid-inducible gene-I (RIG-I) is the prototypical
member of the RLR family, which also includes melanoma
diﬀerentiation-associated gene 5 (MDA5) and laboratory of
genetics and physiology 2 (LGP2). The RLRs have a C-
terminal RNA helicase domain with RNA-binding activity
[35]. RIG-I and MDA5 contain N-terminal tandem cas-
pase activation and recruitment domains (CARDs), but
these are not present within LGP2 (Figure 1(b)). Both
RIG-I and LGP2 are regulated by a C-terminal repressor
domain, which remains unidentiﬁed in MDA5 [36, 37]
(Figure 1(b)). Recent studies have revealed that RIG-I and
MDA5 detect diﬀerent RNA viruses, with RIG-I being
essential for detection of HCV [9, 38]. The mechanism of
PAMP recognition by RIG-I has been best characterized
among the RLRs (presented below). The nature of MDA5
PAMP ligands was recently deﬁned as long-stable double-
stranded (ds) RNA that are distinct from RIG-I ligands
[39].
4.The RoleofRIG-IinNonself Recognitionand
AntiviralInnate Immunity
Early studies previously deﬁned an association between
retinoic acid and ISGexpression wherein it was reported that
the expression of certain ISGs could be in part induced by
retinoic acid [40, 41]. Indeed, in addition to its expression
being induced by retinoic acid, RIG-I is an ISG and its
PRR function may serve to connect IFN and retinoic acid
signaling events that modulate antiviral immunity. RIG-I is
the best characterized of theR L R sa n dw a si m p l i c a t e da s
a PRR through functional cDNA screening that identiﬁed
human RIG-I as positive regulator of ISG expression [42]
and as a PRR of HCV [43]. Structure-function studies
have identiﬁed the RIG-I CARDs as the signaling domain,
which interacts with a downstream molecule, IPS-1, to relay
signaling to IRF-3 and NF-κB. Indeed, overexpression of
t h et a n d e mC A R Da l o n ei ss u ﬃcient to activate down-
stream signaling and subsequent type I IFN production
[35], and the tandem CARD domains are necessary for
RIG-I function [36]. In an interferon-cured HCV replicon
cell, Huh 7.5, the amino acid T55 within the ﬁrst CARD
domain was found to be mutated to an isoleucine, which
associated with loss of innate immune induction by RNA
virus infection and increased permissiveness to HCV RNA
replication compared to RIG-I wild-type parental cells
[43]. This mutation in RIG-I (T55I) has recently been
shown to abrogate RIG-I interaction with the E3 ubiquitin
ligase, TRIM25, to ablate TRIM25-mediated RIG-I ubiqui-
tination that otherwise serves to enhance RIG-I signaling
activation and interaction with the IPS-1 adaptor protein
[44].
Understanding the nature of RIG-I ligand/PAMP RNA
continues to be a major focus of the innate immunity
research ﬁeld. Our current understanding of RIG-I ligand
biology centers on the role of exposed 5
  triphosphate
(5
 ppp) as the central feature of a nonself PAMP ligand
of RIG-I. Various studies have shown that RIG-I can bind
single-stranded (ss) or double-stranded (ds) RNA but in
each case PAMP recognition is dependent upon the RNA
harboring a 5
 ppp. For dsRNA, RIG-I preferentially recog-
nizesRNAlongerthan25-basepairswithanssRNAoverhang
region containing a 5
 -triphosphate (5
 ppp) motif [35, 38].
While RIG-I does not bind to DNA, it selectively binds to
poly(rI:rC) and poly(rA:rU)dsRNA,and poly-U/UCssRNA,
the later identiﬁed as a PAMPmotif within the HCVgenome
[42, 43]. These studies showed that cytoplasmic ssRNA
containing a 5
  triphosphate and uridine- or adenosine-rich
viral RNA motifs of a variety of viruses are well recognized
by RIG-I, and that PAMP RNA binding and innate immune
signaling are governed by the C-terminus repressor domain
(RD) of RIG-I [45].Gastroenterology Research and Practice 3
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Figure 1:(a)The innateimmuneinductionpathwaythrough RLRactivation.HCV5
 ppp RNA withpoly-U/UC motifisshownastheRIG-I
ligand RNA; 5
 ppp dsRNA is depicted beneath MDA5 and could serve as either RIG-I or MDA5 ligand RNA. The site of NS3/4A targeting
of IPS-1 within the RLR pathway during HCV infection is indicated by the arrow, and the resulting signaling blockade is indicated by the
broken line. (b) The RLR family members. CARD, helicase, and C-terminal domains, including the repressor domain (RD), are indicated.
Numbers refer to amino acid (aa) length.
How are endogenous “self” and viral “nonself” RNA
species actually discriminated by RIG-I? As shown in
Figure 2, host RNA synthesis occurs in the nucleus. Unpro-
cessed cellular RNA transcripts contain 5
 -triphosphate.
However,the 5
 -triphosphate ismodiﬁedorprocessedbefore
the transcripts arrive to the cytoplasm; the mRNA acquires a
7-methylguanosine CAPstructure at its 5
  end; tRNAunder-
goes5
  cleavageandaseriesofnucleotidebasemodiﬁcations;
ribosomal RNA, which does possess 5
 ppp, is readily com-
plexed with ribosomal proteins to form ribonucleoprotein
that masks the5
 pppfrom RIG-Irecognition. Indeed, 5
 -OH
or a 5
 -methylguanosine capped RNA do not bind to RIG-
I and therefore cannot promote the conformational change
required for RIG-I activation [36, 45–48]. Endogenous, self
RNAspeciesthusavoiddetectionbyRIG-Iby thepresenceof
a5
  cap, speciﬁc RNA processing, or compartmentalization
as an RNP. Viral RNA, however, either freshly introduced
by infection or produced during viral replication, contains
the essential nonself marker 5
 -triphosphate paired with
other nonself motifs such as dsRNA or ssRNA poly-U/UC4 Gastroenterology Research and Practice
PAMP motifs. Recently, it is reported that cytosolic poly(dA-
dT) DNA motifs are converted into 5
 -triphosphate RNA
by RNA polymerase III within the host cell cytosol and
can thus induce innate immune programs through nonself
recognition of the RNA product by RIG-I [49, 50]. This
pathway may be important in the sensing of Epstein-Barr
virus-encoded small RNAs, which are transcribed by RNA
polymerase III. These ﬁndings suggest that viral and possibly
even certain undeﬁned cellular pol-III transcripts should be
considered as possible PAMP RNA ligands of RIG-I.
The overall structural features of the RLRs deﬁne each as
a DEx/D box RNA helicase. In terms of RIG-I, the helicase
domain and C-terminal RD mediate nonself RNA recogni-
tion and binding of viral PAMP RNA [42]. RIG-I activation
is dependent on PAMP RNA binding and the actions of the
RD such that ectopic expression of full-length RIG-I will not
render signaling of ISG expression unless the RD engages
a speciﬁc RNA PAMP. Functional analyses revealed that
RIG-I is maintained in an autorepressed state through the
RD mediating intermolecular inhibitory interactions with
the CARD and helicase domains [36], and that signaling
activation occurs upon PAMP RNA binding that repositions
the RD and CARDs into a signaling-ON state [36, 51]. RD
repositioning is dependent on ATP hydrolysis activity of
RIG-I, which also serves to drive RIG-I translocation along
a bound RNA to survey for PAMP motifs [52]. By this
model, RIG-I signaling activation proceeds once RIG-I has
engaged a PAMP motif within a bound RNA to thus confer
RD repositioning and release of signaling autorepression.
An important feature of this model is that RIG-I would be
constantly binding and translocating along an RNA until it
encountersa PAMP motif deﬁning speciﬁc ligands as nonself
or until it releases (self) RNA lacking PAMP features. Thus
RIG-I and the RLRs in general may survey the cytosolic
environment for nonself, PAMP RNA. In this sense, RIG-I
is a constant sentinel poised to rapidly detect HCV infection
within the hepatocyte.
5.Triggeringthe Innate Immune
Responseto HCVInfection
As noted above, the nature of the host cell PRR that serves
to detect HCV RNA as nonself and to trigger the innate
immune response to HCV infection was revealed through
studies of the Huh7-derived cell line, termed Huh7.5. This
cell line does not exhibit an intracellular innate immune
response to RNA virus infection and was found to be highly
permissive to supporting HCV RNA replication [43, 53].
cDNA complementation studies identiﬁed RIG-I as a PRR
for HCV RNA wherein RIG-I was ﬁrst thought to bind
to HCV dsRNA motifs located within the viral genome
3
  nontranslated region (NTR). These studies revealed that
RIG-I was essential for triggering the activation of IRF-3 and
NF-κB in response to RNA virus infection in hepatocyte-
derived cells, resulting in IFN-β expression and onset of
theintracellular innate immune response [43].Furthermore,
in cultured cells the HCV NTRs present dsRNA PAMP
structures that may serve as potent agonists of TLR3
signaling [33], though this has not been formally proven in
vivo. Together, these observations suggest that during HCV
infection various RNA motifs are recognized and engaged by
RIG-I and possibly TLR3 to trigger antiviral defenses [43].
The ability of HCV RNA to trigger innate immune
signaling in hepatoma cells and in the liver within in vivo
mouse model was evaluated using molecular approaches to
deﬁne the speciﬁc PAMP motifs responsible for immune
triggering. The outcome of these studies revealed that RIG-
I was essential for innate immune signaling in hepatocytes
and for hepatic innate immunity triggered by HCV RNA
in vivo.T h e3
  NTR of the HCV genome was identiﬁed
as the primary HCV PAMP region that activates RIG-I
signaling [54]. Importantly, this region is critical for HCV
replication [55–58] and consists of three parts: a variable
region containing two stem loops, a poly-U/UC-rich region
that is single stranded and of variable length from 30 tomore
than 100nt, and a conserved “X” region, which contains
three stem loops (Figure 3). These components of the HCV
3
  NTRare presentinall viral genotypes.Itwas expected that
dsRNA or RNA with secondary structure located within the
HCV RNA 3
  NTR would be the primary HCV PAMP for
RIG-I. However, neither the highly structured X region nor
the variable region dsRNA motifs of the HCV genome can
activate RIG-I signaling. Remarkably, the poly-U/UCregion,
in conjunction with the essential 5
 ppp, were identiﬁed as
the HCV PAMP that serves to deﬁne the HCV RNA as
nonself through recognition by RIG-I [54]. Importantly,
while the 5
 ppp was found to be absolutely necessary for
RIG-I recognition of HCV RNA, it was not suﬃcient but
speciﬁcally required the second nonself element, the poly-
U/UCdomainoritsreplicationintermediate(thepoly-A/AG
domain of the negative-strand RNA), for stable binding
to RIG-I that drives the conformation change of the RD
and innate immune signaling activation [46]. Thus, nonself
recognitionofRNAasaPAMPlikelyrequiresmultiplemotifs
of recognition by RIG-I that marks an RNA substrate as
nonself or as a PAMP ligand to speciﬁcally stimulate innate
immunity.
RIG-I signaling activation upon PAMP engagement
results in RIG-I interaction with the downstream adaptor
protein, IFN-beta promoterstimulator1 (IPS-1).RIG-I/IPS-
1 binding is mediated by the CARDs of each protein,
This CARD-CARD interaction takes place on intracellular
membranes and is anchored by IPS-1,leading to recruitment
of a large signaling complex. In hepatocytes, this IPS-
1 “signalosome” drives the activation of IRF-3 and NF-
κB by the IKK and/or Tank-binding kinase 1 (TBK1),
protein kinases, and associated signaling partners. The
exact mechanism by which interaction of RIG-I with IPS-
1 activates signal transduction through IPS-1 remains to be
determined, especially how RIG-I eﬀectively relocalizes to
interactwith IPS-1membrane-associated signaling domains.
Moreover, recent studies now show that NLRX1 and the
C1q receptor, gC1qR, can impart negative regulation to
IPS-1-dependent signaling, indicating that RIG-I signaling
activationmust overcomethisnegative regulationinorderto
impart innate immunity [59–61]. However, the mechanisms
of this regulation and how RIG-I may dominate to driveGastroenterology Research and Practice 5
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positive signaling are not yet known. Moreover, recent
studiesalsoshowthatmitochondriadynamicschangeduring
virus infection to impart enhancement of RIG-I signaling,
but how this inﬂuences HCV infection and immunity is not
deﬁned [62, 63].
6.Evasionof theRIG-I Pathwayby HCV
Despite the fact that HCV RNA can trigger RIG-I signaling
of antiviral innate immunity, approximately 70–80% of all
HCV-infected patients become chronically infected. Several
studies have revealed that HCV can eﬀectively evade various
arms of the innate immune programs that are induced
during infection, and that these outcomes are linked with
an overall adaptive immune deﬁcit that supports persistent
virus replication and chronic infection.
HCV has evolved to counteract the RIG-I pathway [64],
and thisregulation servesto establish the infected hepatocyte
as a platform for the propagation of chronic HCV infection.
HCV evasion of RIG-I is mediated by the essential viral
protein, termed NS3/4A. NS3/4A is a complex of the NS3
and NS4A proteins of HCV and serves to process the HCV
nonstructural proteinsfromtheprecursorHCVpolyprotein.
NS3 interacts with its cofactor, NS4A, to anchor the NS3/4A
complex to intracellular membranes and to facilitate
complete activation of the NS3 protease domain [65, 66].
During the early stages of HCV infection and viral RNA
replication, NS3/4A accumulation supports the targeted
cleavage of IPS-1 by the serine protease activity of the
NS3/4Acomplex[67–69].CleavageofIPS-1byNS3/4Atakes
place near the IPS-1 C-terminal transmembrane domain,
thus revealing IPS-1 and the IPS-1 signalosome from their
membranesubstrate(seeFigure 1(a)).Ithasbeenshownthat
at early hours of HCV infection, the hepatocyteswere able to
relocalize IRF-3 from the cytoplasm to the nucleus; however,
once cleavage of IPS-1 by NS3/4A occurs, which usually can
be detected 24 hours after infection, none of the cells were6 Gastroenterology Research and Practice
found with nuclear IRF-3 [67]. As a result, IPS-1 can no
longer signal downstream to activate IRF-3 and NF-κB, and
the infected cell no longer produced IFN-beta nor expressed
ISGs. IPS-1 cleavage by NS3/4A completely disrupts RLR
signaling and serves to block signaling through the RIG-I
pathway during HCV infection [67, 69–71]. Indeed, IPS-1
mutation at the cleavage motif or NS3/4A protease inhibitor
restores the RIG-I signaling pathway to stimulating the ISG
expression and limit HCV infection [67, 72]. Recent studies
have demonstrated that IPS-1 oligomerization is required
for activation of antiviral innate immune signaling. Thus,
it appears that disrupting IPS-1 oligomerization through
NS3/4A proteolysis could be a contributing mechanism of
RIG-I signaling repression [73, 74]. NS3/4A has also been
shown to cleave the Toll/interleukin-1 receptor/resistance
domain-containing adaptor-inducing IFN (TRIF) protein,
the signaling adaptor molecule for TLR3, to prevent TLR3-
mediated antiviral signaling [75, 76]. While TRIF proteolysis
by NS3/4A would render the infected cell refractory to TLR3
signaling after PAMP ligation, a role for this process in vivo
remains to be demonstrated [77, 78]. Of note is that TLRs,
including TLR3, are themselves ISGs and would be expected
to be induced as a result of RIG-I signaling. In this sense,
the TLR3 axis may represent an important ampliﬁcation
loop that drives and diversiﬁes the antiviral innate immune
response to HCV infection.
7.FutureProspective
Our current understanding of RIG-I regulation by HCV is
thattheviral NS3/4Aprotease is themajor inhibitor ofRIG-I
signaling through its ability to target and cleave IPS-1. Of
high interest is that NS3/4A protease inhibitors are currently
under development as antiviral therapies for HCV [79]. We
have found that these protease inhibitors not only block the
maturation of HCV NS proteins, but also can block the
ability of NS3/4A to cleave IPS-1 and TRIF to restore innate
immune signaling in HCV-infected cells [75, 76]. These fea-
tures of HCV protease inhibitors should oﬀer new treatment
options with the eﬀect of suppressing viral replication while
enhancing the innate immune response to infection. More-
over, these data provide a proof of concept that therapeutic
strategies aimed at enhancing RIG-I signaling could prove
beneﬁcial in the clinic for treating chronic or even acute
viral infections. In addition to suppressing virus infection
directly, the innate immune response serves to drive further
inﬂammatory responses and adaptive immune programs
that ultimately control infection and provide long-lasting
immunity against further viral challenge. In this case, it will
be important to fully understand RIG-I immune regulation
in the context of the global immune response with the goal
of deﬁning sites of immune interaction that can oﬀer thera-
peutic beneﬁt through the developmentand use of immune-
modulator drugs to treat HCV and other viral infections.
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